# Dong‐Wan Kim

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dong-wan-kim/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,791 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 73 |
| i10-index | 272 |
| Last Known Institution | New Generation University College |
| OpenAlex ID | https://openalex.org/A5100638261 |
| ORCID iD | 0000-0001-5124-7132 |
| Works | 725 |

## Researcher papers

Showing 12 of 18.

- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-versus-crizotinib-in-untreated-i-alk-i-positive-non-small-cell-lung/)
- [Virus-Enabled Synthesis and Assembly of Nanowires for Lithium Ion Battery Electrodes](https://scholariq.org/papers/virus-enabled-synthesis-and-assembly-of-nanowires-for-lithium-ion-battery/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)
- [First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/first-line-lorlatinib-or-crizotinib-in-advanced-i-alk-i-positive-lung-cancer/)
- [Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib](https://scholariq.org/papers/predictive-and-prognostic-impact-of-epidermal-growth-factor-receptor-mutation-in/)
- [Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity](https://scholariq.org/papers/preclinical-comparison-of-osimertinib-with-other-egfr-tkis-in-egfr-mutant-nsclc/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial](https://scholariq.org/papers/brigatinib-in-patients-with-crizotinib-refractory-anaplastic-lymphoma-kinase/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-as-first-line-treatment-of-i-egfr-i-mutation-positive-advanced-non/)
- [Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients](https://scholariq.org/papers/elevated-tgf-1-secretion-and-down-modulation-of-nkg2d-underlies-impaired-nk/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [New Generation University College](https://scholariq.org/institutions/new-generation-university-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.